FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2900949525> ?p ?o ?g. }

• W2900949525 endingPage "2150" @default.
• W2900949525 startingPage "2135" @default.
• W2900949525 abstract "Triple-negative breast cancer (TNBC), the most aggressive breast cancer subtype, currently lacks effective targeted therapy options. Eicosapentaenoic acid (EPA), an omega-3 fatty acid and constituent of fish oil, is a common supplement with anti-inflammatory properties. Although it is not a mainstream treatment, several preclinical studies have demonstrated that EPA exerts anti-tumor activity in breast cancer. However, against solid tumors, EPA as a monotherapy is clinically ineffective; thus, we sought to develop a novel targeted drug combination to bolster its therapeutic action against TNBC. Using a high-throughput functional siRNA screen, we identified Ephrin type-A receptor 2 (EPHA2), an oncogenic cell-surface receptor tyrosine kinase, as a therapeutic target that sensitizes TNBC cells to EPA. EPHA2 expression was uniquely elevated in TNBC cell lines and patient tumors. In independent functional expression studies in TNBC models, EPHA2 gene-silencing combined with EPA significantly reduced cell growth and enhanced apoptosis compared with monotherapies, both in vitro and in vivo. EPHA2-specific inhibitors similarly enhanced the therapeutic action of EPA. Finally, we identified that therapy-mediated apoptosis was attributed to a lethal increase in cancer cell membrane polarity due to ABCA1 inhibition and subsequent dysregulation of cholesterol homeostasis. This study provides new molecular and preclinical evidence to support a clinical evaluation of EPA combined with EPHA2 inhibition in patients with TNBC." @default.
• W2900949525 created "2018-11-29" @default.
• W2900949525 creator A5003693436 @default.
• W2900949525 creator A5009306083 @default.
• W2900949525 creator A5019568866 @default.
• W2900949525 creator A5037780494 @default.
• W2900949525 creator A5040329544 @default.
• W2900949525 creator A5044078326 @default.
• W2900949525 creator A5048206365 @default.
• W2900949525 creator A5063903344 @default.
• W2900949525 creator A5065117192 @default.
• W2900949525 creator A5088814426 @default.
• W2900949525 date "2018-11-20" @default.
• W2900949525 modified "2023-10-18" @default.
• W2900949525 title "Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux" @default.
• W2900949525 cites W1562052428 @default.
• W2900949525 cites W1594899067 @default.
• W2900949525 cites W1774029313 @default.
• W2900949525 cites W1898809734 @default.
• W2900949525 cites W1925841406 @default.
• W2900949525 cites W1972561828 @default.
• W2900949525 cites W1978573204 @default.
• W2900949525 cites W2000000810 @default.
• W2900949525 cites W2003217605 @default.
• W2900949525 cites W2018981297 @default.
• W2900949525 cites W2019151692 @default.
• W2900949525 cites W2026358730 @default.
• W2900949525 cites W2030915385 @default.
• W2900949525 cites W2032675622 @default.
• W2900949525 cites W2033576555 @default.
• W2900949525 cites W2034073392 @default.
• W2900949525 cites W2042976627 @default.
• W2900949525 cites W2049767963 @default.
• W2900949525 cites W2074465378 @default.
• W2900949525 cites W2077316345 @default.
• W2900949525 cites W2077605959 @default.
• W2900949525 cites W2077971415 @default.
• W2900949525 cites W2078658791 @default.
• W2900949525 cites W2082072640 @default.
• W2900949525 cites W2089398124 @default.
• W2900949525 cites W2094663537 @default.
• W2900949525 cites W2117692326 @default.
• W2900949525 cites W2125330880 @default.
• W2900949525 cites W2126136644 @default.
• W2900949525 cites W2134642258 @default.
• W2900949525 cites W2139429540 @default.
• W2900949525 cites W2140954822 @default.
• W2900949525 cites W2142739240 @default.
• W2900949525 cites W2143162604 @default.
• W2900949525 cites W2146544786 @default.
• W2900949525 cites W2150868856 @default.
• W2900949525 cites W2152055261 @default.
• W2900949525 cites W2152400573 @default.
• W2900949525 cites W2160295031 @default.
• W2900949525 cites W2160812379 @default.
• W2900949525 cites W2166238906 @default.
• W2900949525 cites W2228907620 @default.
• W2900949525 cites W2261881668 @default.
• W2900949525 cites W2291969078 @default.
• W2900949525 cites W2550876681 @default.
• W2900949525 cites W2580464342 @default.
• W2900949525 cites W2581927139 @default.
• W2900949525 cites W2607153597 @default.
• W2900949525 cites W2610526656 @default.
• W2900949525 cites W2621903338 @default.
• W2900949525 cites W2733958189 @default.
• W2900949525 cites W4252021281 @default.
• W2900949525 doi "https://doi.org/10.1038/s41388-018-0569-5" @default.
• W2900949525 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6430703" @default.
• W2900949525 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30459358" @default.
• W2900949525 hasPublicationYear "2018" @default.
• W2900949525 type Work @default.
• W2900949525 sameAs 2900949525 @default.
• W2900949525 citedByCount "25" @default.
• W2900949525 countsByYear W29009495252019 @default.
• W2900949525 countsByYear W29009495252020 @default.
• W2900949525 countsByYear W29009495252021 @default.
• W2900949525 countsByYear W29009495252022 @default.
• W2900949525 countsByYear W29009495252023 @default.
• W2900949525 crossrefType "journal-article" @default.
• W2900949525 hasAuthorship W2900949525A5003693436 @default.
• W2900949525 hasAuthorship W2900949525A5009306083 @default.
• W2900949525 hasAuthorship W2900949525A5019568866 @default.
• W2900949525 hasAuthorship W2900949525A5037780494 @default.
• W2900949525 hasAuthorship W2900949525A5040329544 @default.
• W2900949525 hasAuthorship W2900949525A5044078326 @default.
• W2900949525 hasAuthorship W2900949525A5048206365 @default.
• W2900949525 hasAuthorship W2900949525A5063903344 @default.
• W2900949525 hasAuthorship W2900949525A5065117192 @default.
• W2900949525 hasAuthorship W2900949525A5088814426 @default.
• W2900949525 hasBestOaLocation W29009495252 @default.
• W2900949525 hasConcept C104317684 @default.
• W2900949525 hasConcept C119056186 @default.
• W2900949525 hasConcept C121608353 @default.
• W2900949525 hasConcept C19038510 @default.
• W2900949525 hasConcept C2776091944 @default.
• W2900949525 hasConcept C2780110267 @default.
• W2900949525 hasConcept C502942594 @default.

• next